March 28, 2025 — Novo Nordisk went shopping this week and brought home a super-early-phase triple-G agonist for the low low price of $200 million in cash up front. On top of that, Novo will pay another $1.8 billion plus royalties if all goes well. That’s a tidy sum to pay for rights to a drug – UBT251 – […]
September 20, 2024 — This year, the Lasker-DeBakey Clinical Medical Research Award recognizes research on GLP-1 receptor biology that is revolutionizing obesity medicine. This is a revolution that is sending shockwaves through all of healthcare and indeed through society. Revolutions are uncomfortable and many people look at progress such as this with regretful nostalgia or outright fear. So we […]
July 14, 2024 — It is hard not to think we are seeing a subtle shift in prevailing bias about obesity. Almost a decade ago, Health Affairs saw merit in publishing projections to say that taxes and other restrictions on unhealthy foods and beverages were more important than providing medical care for children with obesity. The argument was that […]
July 11, 2023 — The emergence of advanced medicines for obesity is teaching us a lot about the overlapping mechanisms that drive desires for alcohol, food, and more. Desire, it seems, is more than just a feeling. It is the product of biological processes that our bodies regulate. But those processes can clearly go astray, and desire for food, […]
October 9, 2018 — Tuesday is obesity medicine day for National Obesity Care Week. And it just so happens that we have two new studies on the subject in the Lancet. They point to a trend. Day by day, we see evidence of more options and better outcomes for medical obesity care. A New Dual-Receptor Agonist Juan Frias and […]
December 11, 2015 — Being different can be uncomfortable and, sometimes, rewarding. A new review in the Annals of Internal Medicine finds only small differences between a rising crop of new, once-weekly drugs for diabetes called GLP-1 agonists. The investigators found a lot of similarities between the outcomes with these drugs, along with some differences in side effects, body weight, […]
November 10, 2015 — If you thought that the onslaught of new studies was done with the closing of ObesityWeek on Friday, think again. Now we have two important new studies of liraglutide and heart disease that were presented at the Annual Scientific Sessions of the American Heart Association (AHA) on Sunday and Monday. The study that’s hogging all the […]
